← Jiangsu Nhwa Pharmaceutical overview

Jiangsu Nhwa Pharmaceutical vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jiangsu Nhwa Pharmaceutical Co Ltd (002262.CS)

Q3 2026
▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

  • First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.

    The half-year results are the period's main hard financial news and show the core business still growing.

  • Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.

    It is the main negative in the results and gives a fair, balanced picture of the period.

  • New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.

    Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.

  • AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.

    It is the period's main corporate action and shows both an AI growth bet and mild dilution.

September 2026
▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

  • First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.

    The half-year results are the period's main hard financial news and show the core business still growing.

  • Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.

    It is the main negative in the results and gives a fair, balanced picture of the period.

  • New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.

    Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.

  • AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.

    It is the period's main corporate action and shows both an AI growth bet and mild dilution.

Latest
▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

  • First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.

    The half-year results are the period's main hard financial news and show the core business still growing.

  • Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.

    It is the main negative in the results and gives a fair, balanced picture of the period.

  • New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.

    Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.

  • AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.

    It is the period's main corporate action and shows both an AI growth bet and mild dilution.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

August 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.